title: Outcomes of acute exacerbation of severe congestive heart failure: quality of life, resource use, and survival. SUPPORT Investigators. The Study to Understand Prognosis and Preferences for Outcomes and Risks of Treatments.
abstract: BACKGROUND
  Congestive heart failure (CHF) is a common disease with high health care costs and high mortality rates. Knowledge of the health-related quality of life outcomes of CHF may guide decision making and be useful in assessing new therapies for this population.
  
  
  METHODS
  A prospective cohort study was conducted involving 1390 adult patients hospitalized with an acute exacerbation of severe CHF (New York Heart Association class III-IV). Demographic data and health-related quality of life were determined by interview; physiologic status and cost and intensity of care were determined from hospital charts.
  
  
  RESULTS
  The median (25th, 75th percentiles) age of patients was 68.0 (58.2, 76.9) years; 61.7% were male. Survival was 93.4% at discharge from the index hospitalization, 72.9% at 180 days, and 61.5% at 1 year. Of patients interviewed at 180 days, the median health rating on a scale of 0 to 100 (0 indicates death; 100, excellent health) was 60 (interquartile range, 50-80), and 59.7% were independent in their activities of daily living. Overall quality of life was reported to be good, very good, or excellent in 58.2% at 180 days. Patients with worse functional capacity were more likely to die. Health perceptions among the patients with available interview data improved at 60 and 180 days after acute exacerbation of severe CHF.
  
  
  CONCLUSIONS
  Patients hospitalized for acute exacerbation of severe CHF have a generally poor 6-month survival, but survivors retain relatively good functional status and have good health perceptions. Furthermore, health perceptions improve after the acute exacerbation.
authors.affiliation: Department of Medicine, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio 44109-1998, USA.
authors.forename: P
authors.initials: P
authors.lastname: Jaagosild
authors.forename: N V
authors.initials: NV
authors.lastname: Dawson
authors.forename: C
authors.initials: C
authors.lastname: Thomas
authors.forename: N S
authors.initials: NS
authors.lastname: Wenger
authors.forename: J
authors.initials: J
authors.lastname: Tsevat
authors.forename: W A
authors.initials: WA
authors.lastname: Knaus
authors.forename: R M
authors.initials: RM
authors.lastname: Califf
authors.forename: L
authors.initials: L
authors.lastname: Goldman
authors.forename: H
authors.initials: H
authors.lastname: Vidaillet
authors.forename: A F
authors.initials: AF
authors.lastname: Connors
mesh_terms: D000208:Acute Disease; D000368:Aged; D005260:Female; D006295:Health Resources / Q000706:statistics & numerical data*; D006333:Heart Failure / Q000150:complications / Q000401:mortality* / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011788:Quality of Life; D012720:Severity of Illness Index; D016019:Survival Analysis; D016896:Treatment Outcome; D014481:United States